Skip to Main Content

Sage Therapeutics said Wednesday that its experimental anti-depression pill alleviated symptoms within three days of treatment, achieving the goal of a clinical trial involving patients with major depressive disorder.

The rapid antidepressant effect of the Sage drug, called zuranolone, is a novel feature that differentiates it from currently available drugs that are slower acting and might be taken for months, if not longer, Sage said.


The company intends to use the results from the study to help position zuranolone as an “episodic” treatment, meaning people with depression take the drug for two weeks and then stop.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment

There was an error saving your display name. Please check and try again.